about
Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers.Transplacental Distribution of Lidocaine and Its Metabolite in Peridural Anesthesia Administered to Patients With Gestational Diabetes MellitusImpact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patientsEnantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS/MS: Application to pharmacokinetics.Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis.Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats.Enantioselective determination of mexiletine and its metabolites p-hydroxymexiletine and hydroxymethylmexiletine in rat plasma by normal-phase liquid chromatography-tandem mass spectrometry: application to pharmacokinetics.Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus.Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene.Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry.Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women.Effective method for the detection of piroxicam in human plasma using HPLC.Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers.Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women.Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transferStereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumathoid arthritisQuantification of piroxicam and 5′-hydroxypiroxicam in human plasma and saliva using liquid chromatography–tandem mass spectrometry following oral administrationChiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic studyEnantioselective analysis of 4-hydroxycyclophosphamide in human plasma with application to a clinical pharmacokinetic studyInfluence of experimental diabetes and insulin treatment on the enantioselective pharmacokinetics of mexiletine and its metabolitesStereoselective Determination of Metoprolol and its Metabolite α-Hydroxymetoprolol in Plasma by LC-MS/MS: Application to Pharmacokinetics during PregnancyStereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography–tandem mass spectrometry: Application in pharmacokineticsAnalysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometryInfluence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patientsSimultaneous analysis of tramadol, O-desmethyltramadol, and N-desmethyltramadol enantiomers in rat plasma by high-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokineticsEnantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: Application to pharmacokineticsTherapy for Neurocysticercosis
P50
Q34657726-03E4BEF5-E57B-4A47-9714-597132AC0EF7Q36047153-FDD0DEF6-2E84-4A06-9EEC-34D4DE939940Q36243677-A9030ABE-7A27-4E21-9C5A-E9164FD46283Q43295639-3EDF1722-0D39-4A51-BC1F-27770F2DB7E2Q44250239-FD5DB1AA-44DA-4496-A7D1-110ABCEDFD86Q45958144-EDF78A11-960B-4279-BB14-151620C4D323Q46116003-F6DC8108-D40B-45CD-AC1D-37F74E7659D2Q46273668-245900B4-64F4-4D52-A279-083A6D10EFF3Q46446345-EE8F08FB-F483-4360-B7EE-3849F9B042B6Q46630335-6CDDF889-EAA0-4410-9EF0-C442F3DFE893Q46915565-214DE632-6A28-4F8C-BDB3-C0227AA26BCBQ47204487-BE84750F-A3B6-44E3-B658-B6609D79EDA8Q47788389-2B70024D-C7A9-40B0-B06D-03774C2EA49CQ49713094-65D95A68-D3F6-4FCB-AD5C-A0CD551DC6C9Q50977791-88E0E9EA-0030-492F-9680-A8D077477604Q53301415-D1FAEA4D-E5A3-4072-B641-2FDBD5CC5034Q58575804-8225C599-7CEF-4BA4-AFC9-17703CEC5F6CQ58851305-552D0F4E-452E-4710-AC2D-CA2E0E56D738Q61792152-FA6352DB-E498-4319-A4DC-5794E1DD1E4FQ62537837-B8145707-F748-4543-9E56-788D934341D6Q62537877-E308DB11-3EB8-4B39-9012-582B05D3737AQ62538065-45DFD9DE-FE4E-4CD6-BB89-4DCB54F5156DQ62538095-17D1F471-AC3D-4540-AACB-4E6C64598C2EQ62538103-86DC1E4F-E475-4097-BC45-C426849C510EQ62538110-B97A9115-D871-4284-AEFD-5CA91F375145Q62538228-38E95ADF-2072-4D4B-9960-623D0FF2A963Q62538308-934809E8-3AA2-4E36-8826-2684F107E7E6Q62539051-89DB9B76-3219-4FF4-8186-FCB6971973B4Q62542262-A32C51C5-8706-4B6B-897B-1123DB8FEF7B
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-2171-7804
@en
name
Maria Paula Marques
@ast
Maria Paula Marques
@en
Maria Paula Marques
@es
Maria Paula Marques
@nl
type
label
Maria Paula Marques
@ast
Maria Paula Marques
@en
Maria Paula Marques
@es
Maria Paula Marques
@nl
prefLabel
Maria Paula Marques
@ast
Maria Paula Marques
@en
Maria Paula Marques
@es
Maria Paula Marques
@nl
P106
P21
P31
P496
0000-0003-2171-7804